ConvaTec Group stock
Price history
+13.30% over the period1 year: from 234.60 GBp (November 20, 2025) to 265.80 GBp (November 20, 2026), +13.30%.
Show chart data
Closing prices adjusted for splits: the last close of each month.
| Date | Close |
|---|---|
| November 20, 2026 | 265.80 GBp |
| October 30, 2026 | 244.40 GBp |
| September 30, 2026 | 217.00 GBp |
| August 28, 2026 | 227.60 GBp |
| July 31, 2026 | 224.00 GBp |
| June 30, 2026 | 215.00 GBp |
| May 29, 2026 | 202.20 GBp |
| April 30, 2026 | 210.80 GBp |
| March 31, 2026 | 215.40 GBp |
| February 27, 2026 | 256.40 GBp |
| January 30, 2026 | 230.00 GBp |
| December 31, 2025 | 243.20 GBp |
| November 28, 2025 | 235.60 GBp |
| November 20, 2025 | 234.60 GBp |
At a glance
The company
Develops, manufactures and sells medical products and technologies for wound care, ostomy care, continence care and infusion care
Latest results
Quarter to June 30, 2026 · EPS $0.09 (estimate $0.09)
Next event
TickerLandia's take on ConvaTec Group
- Pricier than similar companies: trailing 12-month P/E 53 vs 34 (+55%) in a group of 10.
- Strong point: Market momentum (84/100 in its group). Weak point: Growth (28/100).
Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks
Where the price stands
−2.49% from the 52-week high
Analysts · 19 analysts
Average target312.17 GBp+17.45% vs. price
Buy 18 · Hold 1 · Sell 0 · Strong buy
TickerLandia Fingerprint: ConvaTec Group
Compared with similar companies: very strong momentum.
Financials and price compared with 34 companies in the medical instruments & supplies industry, worldwide. Momentum and risk compared with 1,160 European stocks.
Priceaverage41
How much it costs relative to what it produces.
Metric Value Position in group P/E (trailing 12 months) 53.2 72 Forward P/E 15.5 22 EV/EBITDA 11.8 22 Price/book 4.87 60 Price/sales 2.04 31 Profitabilityaverage46
How much it earns on revenue and capital.
Metric Value Position in group Gross margin 56.0% 57 ROA 6.7% 60 Operating margin 16.3% 54 Net margin 5.0% 19 ROE 7.7% 37 Earnings stabilityhigh63
How steady its margins were over the last five annual reports.
Metric Value Position in group Loss-making yearscounts in reverse: lower means more earnings stability 0 of 5 annual reports 63 Margin variabilitycounts in reverse: lower means more earnings stability 2.3% 63 Growthlow28
How fast revenue and earnings are growing.
Metric Value Position in group Average revenue growth (3 years) +5.58% 49 Earnings growth (year over year) −47.10% 5 Revenue growth (year over year) +4.40% 31 Financial strengthlow35
How well it would weather a hard period: debt, liquidity, interest.
Metric Value Position in group Current ratio 1.93 54 Interest coverage 6.61 45 Debt/equitycounts in reverse: lower means more financial strength 1.22 14 Net debt/EBITDAcounts in reverse: lower means more financial strength 2.47 27 Dividendhigh65
How much it returns to shareholders, and for how long.
Metric Value Position in group Consecutive dividend years at least 10 years 29 Payout ratiopays out more than its earnings 111.7% 90 Dividend yield 2.3% 76 Market momentumvery strong84
How the stock has moved compared with the market.
Metric Value Position in group Relative strength (3 months) +22.40% 95 Relative strength (6 months) +25.12% 90 Distance from 200-day average +18.33% 91 1-year return +13.30% 57 Riskaverage55
How much the price swings.
Metric Value Position in group Volatility (60 days) 29.7% 58 Beta (1 year) 0.84 58 Maximum drawdown (12 months) 24.3% 50
Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 22, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated
Valuation
ConvaTec Group is pricier than similar companies
ConvaTec Group's P/E (trailing 12 months): 53.2, +55% against the median of a group of 10 similar companies (34.2).
Compared with 10 similar companies
| Metric | ConvaTec Group | Position in the group | Band |
|---|---|---|---|
| P/E (trailing 12 months) | 53.2 | High | |
| Forward P/E | 15.5 | Low | |
| Operating margin | 16.3% | Middle | |
| ROE | 7.7% | Low | |
| Debt/equity | 1.22 | High |
Grey band: the middle half of the group; tick: the median; dot: ConvaTec Group. All multiples and dividends
TickerLandia analysisHow it is calculated
The financials
The business in numbers
Revenue
$1.23B
Latest quarter · Q2 2026
Net income
$54M
Latest quarter · Q2 2026
Quarterly net margin
4.4%
Latest quarter · Q2 2026
Numbers and valuation
Full valuation- Market cap
- £5.07B
- P/E
- 53.2
- EPS
- 5.00 GBp
- Volume
- 6.52M
- Daily trading
- €25.89M
- Dividend yield
- 2.10%
- Last ex-dividend on August 20, 2026
How ConvaTec Group is changing
All resultsRevenue grew 5.2% a year on average over the last 5 years
Operating margin rose from 11.8% to 16.8%
Profits turn into cash: free cash flow equal to 177% of net income
Returns
ConvaTec Group returns with dividends
£1,000 invested in ConvaTec Group 5 years ago, on November 22, 2021, would be worth £1,382 today with dividends reinvested: +38.15% in total, +6.69% per year. On price alone it would be £1,243 (+24.26%).
| Period | ConvaTec Group | FTSE 100 | £1,000 becomes |
|---|---|---|---|
| 1 month | +12.91% | −3.60% | £1,129 |
| 6 months | +24.09% | −0.82% | £1,241 |
| Year to date | +9.29% | +4.18% | £1,093 |
| 1 year | +16.02% | +8.59% | £1,160 |
| 3 years | +26.76% | +38.02% | £1,268 |
| 5 years | +38.15% | +42.60% | £1,382 |
| 10 years | +38.93% | +52.65% | £1,389 |
Over the last 6 months it has done better than 57% of the stocks in the Healthcare sector.
From 1 year up with dividends reinvested, before taxes; under a year price only. FTSE 100: price only. Calculate your investment
The chart in detail
ConvaTec Group: technical analysis
ConvaTec Group is in an uptrend: the price is above its 50- and 200-session moving averages, and the 200-session average is rising. The price is 22.7% below its all-time closing high (344.00 GBp, June 5, 2017).
- Trend
- Upward
- RSI (14 sessions)
- 66
- Between 30 and 70
- vs 200-session average
- +18.33%
Support and resistance
Price areas where ConvaTec Group has stopped several times in the last year. They describe the chart; they are not forecasts.
- No resistance above: the price is near the highs of the year
- Last price265.80 GBp
- Support245.37 GBp−7.69%3 touches, last on October 26, 2026
- Support236.92 GBp−10.87%5 touches, last on November 4, 2026
- Support227.70 GBp−14.33%2 touches, last on March 27, 2026
Volatility and risk
Over the last year it has moved roughly in line with the FTSE 100.
- Beta (1 year) vs FTSE 100
- 0.84
- Volatility (60 sessions, annualised)
- 29.7%
- Largest fall in the last year
- −24.34%
Close of November 20, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it
ConvaTec Group: seasonality
Average monthly price change over 10 years
Over the last 10 years, the strongest month for ConvaTec Group has been March: +3.74% on average, positive in 6 years out of 10. The weakest has been October: −3.42% on average, positive in 5 years out of 10. November, the current month, has been positive in 4 years out of 10 (+1.24% on average).
Show chart data
| Month | Average | Median | Positive years |
|---|---|---|---|
| January | +0.81% | +0.59% | 6 of 10 |
| February | +0.08% | +0.34% | 5 of 10 |
| March | +3.74% | +2.98% | 6 of 10 |
| April | +2.28% | −0.33% | 5 of 10 |
| May | +1.70% | +1.30% | 6 of 10 |
| June | −0.10% | +0.47% | 5 of 10 |
| July | −0.18% | +1.68% | 6 of 10 |
| August | +0.26% | −0.62% | 5 of 10 |
| September | −2.96% | −4.59% | 2 of 10 |
| October | −3.42% | +0.02% | 5 of 10 |
| November | +1.24% | −1.93% | 4 of 10 |
| December | +0.25% | +0.56% | 6 of 10 |
Price change only, dividends excluded. Past seasonality does not predict future moves.
The company
ConvaTec Group and its competitors
With 10,000 employees, ConvaTec Group Plc develops, manufactures and sells medical products and technologies for managing chronic conditions, mainly in Europe, North America and other international markets. Its wound care range covers chronic wounds linked to diabetes as well as acute wounds from trauma and burns, while its ostomy solutions serve people with a stoma after colorectal or bladder cancer, inflammatory bowel disease or injury.
- Headquarters
- London, United Kingdom
- Employees
- 10,000
- Founded
- 1978
- Chief executive
- Jonathan Mason
| Company | Market cap | Operating margin | P/E (trailing 12 months) | 6 months |
|---|---|---|---|---|
| ConvaTec GroupCTEC | $6.66B | 16.3% | 53.2 | +24.09% |
| Ypsomed HoldingYPSN | $6.9B | 31.0% | 34.9 | +30.53% |
| Fielmann GroupFIE | $3.93B | 13.7% | 16.4 | −3.95% |
| SCHOTT Pharma1SXP | $3.74B | 16.4% | 25.1 | +34.04% |
| Tecan GroupTECN | $3.58B | 4.9% | — | +64.44% |
| Carl Zeiss MeditecAFX | $3.07B | 7.2% | 23.3 | +24.32% |
Same industry or related industries, similar size. Compare ConvaTec Group with its competitors · Full profile
